To determine if differences in NMT2 protein levels correlated with disease prognosis in these breast cancer patients, we performed Kaplan–Meier overall survival (OS) analysis using the clinical outcomes associated with each breast adenocarcinoma sample. Here, NMT2 is linked to breast adenocarcinoma.